Suppr超能文献

一站式融合基因 panel 在检测肾细胞癌中 TFE3/TFEB 基因重排和扩增的诊断效用。

Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.

机构信息

Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.

Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy.

出版信息

Mod Pathol. 2021 Nov;34(11):2055-2063. doi: 10.1038/s41379-021-00858-y. Epub 2021 Jun 19.

Abstract

MiT family translocation renal cell carcinoma (MiT-RCC) harbors translocations involving the TFE3 or TFEB genes. RCC with TFEB amplification is also identified and is associated with a more aggressive clinical course. Accurate diagnosis of MiT-RCC is crucial for patient management. In this study, we evaluated the performance of the Archer FusionPlex assay for detection of MiT-RCC with TFE3 or TFEB translocations and TFEB amplifications. RNA was extracted from 49 RCC FFPE tissue samples with known TFE3/TFEB status (26 TFE3 FISH positive, 12 TFEB FISH positive, 4 TFEB amplified (1 case both split and amplified), and 8 FISH negative) using the Covaris extraction kit. Target enriched cDNA libraries were prepared using the Archer FusionPlex kit and sequenced on the Illumina NextSeq 550. We demonstrate that the age of the specimen, quality of RNA, and sequencing metrics are important for fusion detection. Fusions were identified in 20 of 21 cases less than 2 years old, and TFE3/TFEB rearrangements were detected in all cases with Fusion QC ≥ 100. The assay identified intrachromosomal inversions in two cases (TFE3-RBM10 and NONO-TFE3), usually difficult to identify by FISH assays. TFEB mRNA expression and the TFEB/TFE3 mRNA expression ratio were significantly higher in RCCs with TFEB fusion and TFEB gene amplification compared to tumors without TFEB fusion or amplification. A cutoff TFEB/TFE3 ratio of 0.5 resulted in 97.3% concordance to FISH results with no false negatives. Our study demonstrates that the FusionPlex assay successfully identifies TFE3 and TFEB fusions including intrachromosomal inversions. Age of the specimen and certain sequencing metrics are important for successful fusion detection. Furthermore, mRNA expression levels may be used for predicting cases harboring TFEB amplification, thereby streamlining testing. This assay enables accurate molecular detection of multiple subtypes of MiT-RCCs in a convenient workflow.

摘要

TFE3 或 TFEB 基因重排的 MiT 家族易位性肾细胞癌(MiT-RCC)。还鉴定出具有 TFEB 扩增的 RCC,并且与更具侵袭性的临床过程相关。MiT-RCC 的准确诊断对于患者管理至关重要。在这项研究中,我们评估了 Archer FusionPlex 检测 TFE3 或 TFEB 易位和 TFEB 扩增的 MiT-RCC 的性能。使用 Covaris 提取试剂盒从 49 个具有已知 TFE3/TFEB 状态的 RCC FFPE 组织样本中提取 RNA(26 个 TFE3 FISH 阳性,12 个 TFEB FISH 阳性,4 个 TFEB 扩增(1 例既有分裂又有扩增),8 个 FISH 阴性)。使用 Archer FusionPlex 试剂盒制备靶向富集 cDNA 文库,并在 Illumina NextSeq 550 上进行测序。我们证明了标本的年龄、RNA 质量和测序指标对于融合检测很重要。在小于 2 年的 21 个病例中鉴定出融合,在 Fusion QC≥100 的所有病例中均检测到 TFE3/TFEB 重排。该检测在两个病例中(TFE3-RBM10 和 NONO-TFE3)鉴定出染色体内倒位,通常难以通过 FISH 检测来鉴定。与没有 TFEB 融合或扩增的肿瘤相比,具有 TFEB 融合和 TFEB 基因扩增的 RCC 中 TFEB mRNA 表达和 TFEB/TFE3 mRNA 表达比值显着升高。TFEB/TFE3 比值为 0.5 的截断值与 FISH 结果的一致性为 97.3%,无假阴性。我们的研究表明,FusionPlex 检测成功地鉴定了 TFE3 和 TFEB 融合,包括染色体内倒位。标本的年龄和某些测序指标对于成功的融合检测很重要。此外,mRNA 表达水平可用于预测携带 TFEB 扩增的病例,从而简化测试。该检测方法可在方便的工作流程中准确地检测多种 MiT-RCC 亚型的分子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验